Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints
Survival rates for metastatic lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), are poor with 5-year survivals of less than 5%. The immune system has an intricate and complex relationship with tumorigenesis; a groundswell of research on the immune system is...
Main Authors: | Niki Karachaliou, Maria Gonzalez Cao, Cristina Teixidó, Santiago Viteri, Daniela Morales-Espinosa, Mariacarmela Santarpia, Rafael Rosell |
---|---|
Format: | Article |
Language: | English |
Published: |
China Anti-Cancer Association
2015-06-01
|
Series: | Cancer Biology & Medicine |
Subjects: | |
Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/844 |
Similar Items
-
Assays for predicting and monitoring responses to lung cancer immunotherapy
by: Cristina Teixidó, et al.
Published: (2015-06-01) -
Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
by: Lucas V. dos Santos, et al.
Published: (2021-03-01) -
The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
by: Qingshui Wang, et al.
Published: (2017-11-01) -
Advances in immunotherapy for treatment of lung cancer
by: Jean G. Bustamante Alvarez, et al.
Published: (2015-09-01) -
Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas
by: Kazuhiko Hashimoto, et al.
Published: (2021-07-01)